We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Consensus PT $8.89 · 9 analysts
Stored first · Google News · Yahoo Finance (English)
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Report - Results, Call & Slides TipRanks
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Report - Results, Call & Slides - TipRanks
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Report - Results, Call & Slides TipRanks
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation ACCESS Newswire
Enterprise value to EBIT forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Enterprise value to EBIT forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST TradingView
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I - The National Law Review
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I The National Law Review
Form 144 Aquestive Therapeutics For: 15 July By Investing.com - Investing.com South Africa
Form 144 Aquestive Therapeutics For: 15 July By Investing.com Investing.com South Africa
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.12 | — | — | $11.56M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.24 | — | — | $8.72M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.32 | — | — | $45.69M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.19 | — | — | $32.15M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 11. 07. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2025. 10. 09. | JMP Securities | — | Maintain | Market Outperform → Market Outperform | — | JMP Securities: Market Outperform |
| 2025. 09. 08. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2025. 06. 17. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 05. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 04. 02. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,139,404 | $4.73M | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 381,120 | $2.46M | 0.00% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 283,734 | $1.18M | 0.00% | — | New position |